Antivirals Tied to Heart Issue in COVID Patients
FRIDAY, July 10, 2020 (HealthDay News) — Older, critically ill COVID-19 patients who are given a combination of two common antiretroviral drugs can experience a drastic slowing of their heart rate, French researchers report.
In their study of 41 patients treated with lopinavir and ritonavir twice daily for 10 days, 22% developed a slow heart rate condition called bradycardia. When the drugs were stopped or doses lowered, the patients’ heart rates returned to normal, according to the team from Amiens University Hospital, in France.
“There are extensive investigations underway to find therapies that are effective at treating patients infected with COVID-19,” said Dr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, who had no part in the study.
The lopinavir-ritonavir combo had been considered a promising treatment for COVID-19 based on very small reports, randomized clinical trials and off-label use, Fonarow said.
But earlier studies have suggested that this combination may also lead to heart block, a problem with electrical signals in the heart. “Determining how these drugs lead to the bradycardia will require further study,” Fonarow said.
Doctors prescribing these drugs should be aware of the potential for bradycardia and carefully monitor patients, he added.
“Moreover, preliminary clinical trial results suggest this therapy is not effective in COVID-19, so use in this setting will likely be very limited going forward,” Fonarow said.
Lopinavir and ritonavir have also been used to treat other viruses, including SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome) and HIV. The researchers noted that bradycardia has also been seen among HIV patients treated with the drugs.
Normally, adults’ hearts beat between 60 and 100 times a minute. In bradycardia, the rate falls below 60 beats per minute, causing decreased blood flow that can lead to fainting, chest pain, low blood pressure and heart failure.
Patients in the French study who developed the problem were older than ones who did not, averaging 62 to 80 years of age, the researchers reported.
Dr. Marc Siegel, a professor of medicine at NYU Langone Medical Center in New York City who reviewed the findings, noted that the two-drug combo had not helped hospitalized COVID-19 patients in other recent trials.